Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 4/20 | 0.47 |
| ▸ | TYK2 | P29597 | 3/20 | 0.45 |
| ▸ | JAK2 | O60674 | 1/20 | 0.45 |
| ▸ | JAK1 | P23458 | 1/20 | 0.45 |
| ▸ | JAK3 | P52333 | 1/20 | 0.45 |
| ▸ | CDK1 | P06493 | 4/20 | 0.43 |
| ▸ | CDK2 | P24941 | 4/20 | 0.43 |
| ▸ | CDK9 | P50750 | 4/20 | 0.43 |
| ▸ | NTRK1 | P04629 | 3/20 | 0.42 |
| ▸ | TBK1 | Q9UHD2 | 3/20 | 0.42 |
| ▸ | CA2 | P00918 | 3/20 | 0.42 |
| ▸ | NUAK1 | O60285 | 2/20 | 0.42 |
| ▸ | STK16 | O75716 | 2/20 | 0.42 |
| ▸ | CSNK2A2 | P19784 | 2/20 | 0.42 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.42 |
| ▸ | BMP2K | Q9NSY1 | 2/20 | 0.42 |
| ▸ | CSF1R | P07333 | 1/20 | 0.42 |
| ▸ | ULK3 | Q6PHR2 | 1/20 | 0.42 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.42 |
| ▸ | IKBKB | O14920 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1633835 | 0.86 | IKBKB (0.47) | TYK2CDK1CDK2CDK9NTRK1 | |
| SCHEMBL1631354 | 0.84 | TYK2 (0.54) | SYKTYK2JAK2JAK1JAK3 | |
| SCHEMBL1633715 | 0.84 | NTRK1 (0.42) | SYKTYK2CDK1CDK2CDK9 | |
| SCHEMBL1633031 | 0.84 | FGFR4 (0.47) | TYK2CDK1CDK2CDK9NTRK1 | |
| SCHEMBL1632397 | 0.84 | TBK1 (0.57) | TYK2JAK2JAK3CDK1CDK2 | |
| SCHEMBL1633356 | 0.82 | CDK1 (0.44) | TYK2JAK2JAK1JAK3CDK1 | |
| SCHEMBL1633354 | 0.82 | CDK1 (0.44) | TYK2JAK2JAK1JAK3CDK1 | |
| SCHEMBL1633514 | 0.82 | CDK1 (0.44) | TYK2JAK2JAK1JAK3CDK1 | |
| SCHEMBL1632154 | 0.81 | CDK2 (0.46) | TYK2CDK1CDK2CDK9NTRK1 | |
| SCHEMBL1633063 | 0.79 | IKBKB (0.53) | CDK1CDK2CDK9CA2IKBKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7932262-B2 | Quinazolines for PDK1 inhibition | NOVARTIS AG (CH) | 2011-04-26 | — | — | US | disclosed |
| US-7932262-B2 | Quinazolines for PDK1 inhibition | NOVARTIS AG (CH) | 2011-04-26 | — | — | US | disclosed |
| US-7932262-B2 | Quinazolines for PDK1 inhibition | NOVARTIS AG (CH) | 2011-04-26 | — | — | US | disclosed |
| US-20100048561-A1 | QUINAZOLINES FOR PDK1 INHIBITION | NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048561-A1 | QUINAZOLINES FOR PDK1 INHIBITION | PDK1, PDK2, PDK3 | SYK 4204/4885TYK2 1796/4885JAK2 1352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.